<\/b><\/p>\n
<\/b><\/p>\n
FRIDAY, March 20, 2020 (HealthDay News) — Lopinavir-ritonavir treatment offers no significant benefit over standard care for hospitalized adult patients with severe coronavirus 2019 (COVID-19) infection, according to a study published online March 18 in the New England Journal of Medicine<\/i>.<\/p>\n
Bin Cao, M.D., from the National Clinical Research Center for Respiratory Diseases in Beijing, and colleagues randomly assigned hospitalized adult patients with confirmed SARS-CoV-2 infection to receive either lopinavir-ritonavir twice a day for 14 days in addition to standard care or standard care alone (99 and 100 patients, respectively).<\/p>\n
The researchers found that the time to clinical improvement did not differ for treatment with lopinavir-ritonavir versus standard care alone (hazard ratio, 1.24; 95 percent confidence interval, 0.90 to 1.72). Mortality at 28 days was similar in the groups (19.2 versus 25.0 percent; difference, \u22125.8 percent; 95 percent confidence interval, \u221217.3 to 5.7). Similar percentages of patients with detectable viral RNA were seen at various time points. In a modified intention-to-treat analysis, the median time to clinical improvement was one day shorter with lopinavir-ritonavir than standard care (hazard ratio, 1.39; 95 percent confidence interval, 1.00 to 1.91).<\/p>\n
“Lopinavir-ritonavir treatment did not significantly accelerate clinical improvement, reduce mortality, or diminish throat viral RNA detectability in patients with serious COVID-19,” the authors write.<\/p>\n
Abstract\/Full Text<\/a><\/p>\n